Hagens Berman probes Ionis after 23% stock drop on trial failure

The law firm said it is examining whether Ionis was sufficiently transparent about its Phase 3 eplontersen study after the July 9 result erased more than $3.3 billion in market value.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.